AptarGroup, Inc. (ATR) announced Monday it's acquired Sommaplast, a Brazilian company that makes the kind of pharma packaging you probably don't think about but definitely use—closures, droppers, dispensers, and dosing cups for oral medications.
The deal, valued at roughly $30 million to $35 million, isn't exactly a blockbuster acquisition, but it fits neatly into Aptar's strategy of expanding its pharmaceutical packaging business through targeted bolt-on deals.
"Aptar has manufactured in Brazil for 25 years and this acquisition is expected to further reinforce our footprint in the region. It also helps position us to capitalize on Brazil's fast-growing oral dosing, over-the-counter and nutraceutical markets...," explained Gael Touya, President of Aptar Pharma.
Sommaplast has been around for more than two decades and runs operations from São Paulo with a workforce exceeding 400 people. For Aptar, which already operates manufacturing facilities in Cajamar, Jundiaí, Maringá, and Camaçari across Brazil, this acquisition consolidates its regional presence and brings complementary manufacturing capabilities under one roof.
What Analysts Are Saying
William Blair analyst Matt Larew weighed in Tuesday, acknowledging the deal's modest size. "While a small deal (initial revenue and profitability contribution is expected to be de minimis), Sommaplast appears to be a solid fit within Aptar's Pharma business as we see synergy capture potential and we like seeing the company lean further into its Pharma expansion strategy with small, bolt-on acquisitions such as this one," Larew wrote.
From a valuation perspective, Aptar trades at 20.7 times William Blair's 2026 adjusted EPS estimate. That's below the company's historical average of 26.4 times since it acquired Stelmi back in 2012. It's also a discount compared to pure-play pharma packaging peers trading around 27 times, though still at a premium to consumer packaging companies at roughly 14 times.
Looking beyond 2026, Larew thinks total returns could reach low double digits. But there are headwinds to consider—namely the loss of high-margin Narcan sales in 2026 and uncertainty around performance in Aptar's Beauty and Closures segments. William Blair expects earnings growth to remain relatively muted in the near term and maintains a Market Perform rating.
ATR Price Action: AptarGroup shares were down 1.43% at $121.52 at the time of publication on Tuesday.
